NeoPharm 1Q26: Revenue & Net Profit Growth, Dividend Increase

1Q26 revenue ₩36.2B (+14.6% YoY), operating profit ₩8.7B, net profit ₩8.6B (+21% YoY)
DPS increased to ₩750 (from ₩600, +25%), total dividend ₩11.7B
Corporate credit rating AA- (Korea Rating Data, July 2025)
Consolidated subsidiary (Shanghai) liquidated, individual financial statements from this quarter
Litigation risk: TheBioLab claims ₩1.4B damages, ongoing (management deems immaterial)
Strong liquidity: cash ₩31.9B, short-term financial assets ₩117.4B
Debt ratio 17.3% (vs 11.5% at year-end), sound financial structure